Biotechnology Innovation Organization

SAN DIEGO (June 22, 2026) - The BIO International Convention (BIO 2026), the world’s largest and most comprehensive event for the biotechnology industry, begins today in San Diego. The convention brings together 20,000+ biotech and life sciences leaders from around the world. This year’s theme, “Driven by Purpose,” reflects the industry’s commitment to solve the impossible, push boundaries, and deliver better outcomes for patients, public health, and the world.

At BIO 2026, where science meets real-world impact, you can access more than 150 sessions across 18 focus areas with discussions from leading experts. Use the search, filter, and AI generate itinerary tools to plan out your calendar with your own “must see” sessions, or find sessions by job role (from the main navigation). Accelerate your career growth by adding a Professional Development Course to your BIO 2026 registration. Learn more.

This session will explore how pharma/biotech companies achieve pipeline diversity through portfolio strategy, strategic collaborations, and scientific rigor. The conversation will examine the processes behind diversification, including how companies identify emerging opportunities, leverage external innovation, allocate resources across modalities and disease areas, and adapt to evolving market and scientific landscapes.

In biotech, success often hinges on spotting opportunities before anyone else does. Some of the industry’s most impactful companies have been built with smart business development regardless of their R&D bench that transforms their companies by advancing them into the next drug development stage, expanding their therapeutic areas to pursue other commercial markets, and creating favorable long-term financial positions.

The next evolution of AI in biopharma is already here - systems designed not just to analyze data but to make decisions. These “agentic AI” models can set goals, adapt strategies, and generate hypotheses with a degree of autonomy that could reshape discovery and development. What is at stake is more than efficiency - it is a shift in perception. AI is no longer only a supportive tool but is beginning to be viewed as a potential teammate in scientific problem solving.

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 -- legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia.

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the resignation of FDA Commissioner Marty Makary. “Dr. Makary inherited an FDA in crisis after the DOGE changes, which included the firing of thousands of employees. These staffing and morale challenges were compounded by constant leadership changes over the past year and questions around shifting FDA standards for drug approvals.

WASHINGTON, DC (April ​15​​,​ 2026) – Today, the Biotechnology Innovation Organization (BIO) announced the launch of ​​The Fight of Our Lives, a new national campaign focused on the stories behind biotechnology breakthroughs, the patients whose lives depend on them, and the scientists working to make them possible.